NMTRQ (9 Meters Biopharma) Cyclically Adjusted PS Ratio: (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is 9 Meters Biopharma Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


9 Meters Biopharma  (OTCPK:NMTRQ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


9 Meters Biopharma Cyclically Adjusted PS Ratio Related Terms


9 Meters Biopharma Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for 9 Meters Biopharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

9 Meters Biopharma Cyclically Adjusted PS Ratio Chart

9 Meters Biopharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

9 Meters Biopharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NMTRQ vs USRM, NOVNQ, ONCSQ: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, 9 Meters Biopharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


9 Meters Biopharma Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 9 Meters Biopharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where 9 Meters Biopharma's Cyclically Adjusted PS Ratio falls into.



9 Meters Biopharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

9 Meters Biopharma's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec22 is calculated as:

For example, 9 Meters Biopharma's adjusted Revenue per Share data for the fiscal year that ended in Dec22 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec22 (Change)*Current CPI (Dec22)
=0/296.7970*296.7970
=0.000

Current CPI (Dec22) = 296.7970.

9 Meters Biopharma Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201312 127.556 233.049 162.448
201412 420.111 234.812 531.011
201512 306.148 236.525 384.162
201612 145.179 241.432 178.471
201712 0.000 246.524 0.000
201812 0.000 251.233 0.000
201912 0.000 256.974 0.000
202012 0.000 260.474 0.000
202112 0.000 278.802 0.000
202212 0.000 296.797 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


9 Meters Biopharma Business Description

Address 4509 Creedmoor Road, Suite 600, Raleigh, NC, USA, 27612
9 Meters Biopharma Inc is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. Its pipeline includes vurolenatide, a proprietary Phase 3 long-acting glucagon-like-peptide 1 (GLP-1) agonist for short bowel syndrome (SBS) and a robust pipeline of early-stage candidates for undisclosed rare diseases and/or unmet needs.